Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...

Bleakley Financial Group LLC raised its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 49.9% in the 4th quarter, according to the company in its most recent filing with the Securities & ...

Terra Wonsettler, PharmD, MBA, vice president of pharmacy for Evolent, discusses the recent HHS OIG report that stemmed from ...

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

Here we go again. With Aduhelm largely sidelined, Biogen and Eisai are hoping for a better fortunes with their next Alzheimer's disease therapy lecanemab, which is now fully filed with the FDA.

From the beginning, the approval of its Aduhelm (aducanumab) treatment was met with controversy – over the interactions with the FDA, and the advisor committee’s vote against the treatment ...

A reporter uncovers evidence that research fraud on a massive scale has hyped the potential benefit of expensive drugs aimed ...

In 2022, the Medicare Part B standard premium will increase from $148.50 to $170.10. This $21.60 increase (14.5%) is the largest since the Medicare program began in 1965 and much higher than was ...

I’m really annoyed, on behalf of the journalist Charles Piller, about the release date of his book “ Doctored: Fraud, ...